---
title: "Rinzimetostat (ORIC-944) in Metastatic castration-resistant prostate cancer previously treated with abiraterone, in combination with darolutamide: Product comparison"
description: "Formulary evidence on Rinzimetostat (ORIC-944) in Metastatic castration-resistant prostate cancer previously treated with abiraterone, in combination with darolutamide: Product comparison. Topics: Mevrometostat plus enzalutamide: randomized phase 1 dose expansion after abiraterone; Mevrometostat plus enzalutamide: dose escalation after abiraterone or enzalutamide; Mevrometostat 875 mg with food plus enzalutamide: safety and selection of the phase 3 dose; Mevrometostat 875 mg with food plus enzalutamide: efficacy after abiraterone, enzalutamide naive; 14 further topics. 18 evidence topics quoted from 19 sources."
canonical: "https://www.evicenter.com/drugs/rinzimetostat--metastatic-castration-resistant-prostate-cancer-previously-treated-with-abiraterone-in-combination-with-darolutamide/product-information-and-disease-description/product-comparison"
published: "2026-11-15T21:45:22-05:00"
modified: "2026-11-17T19:46:25-05:00"
---

# Rinzimetostat (ORIC-944) in Metastatic castration-resistant prostate cancer previously treated with abiraterone, in combination with darolutamide: Product comparison

<a id="heading-2.1.2.14"></a>

## 2.1.2.14 Product comparison

<a id="topic-2.1.2.14-1"></a>

### Mevrometostat plus enzalutamide: randomized phase 1 dose expansion after abiraterone

> “Pts with mCRPC who received prior abiraterone, ≤1 prior chemotherapy in any setting, with evidence of progression per modified Prostate Cancer Working Group 3 criteria were included. Pts receiving ADT were randomized 1:1 to M (orally, 1250 mg BID on empty stomach) + E (160 mg QD) or E, stratified by prior chemotherapy.”
> “As of Sept 2, 2024,81 pts were included (M+E, n=41; E, n=40). Median (IQR) follow-up was 9.6 (3.1-14.5) mo.”
> “Median (95% CI) rPFS was 14.3 (7.5, not estimable) mo for M+E and 6.2 (4.1, 13.9) mo for E (hazard ratio 0.51; 90% CI 0.28, 0.95).”
> “Confirmed PSA50 (95% CI) was observed in 34.1% (20.1, 50.6) of pts for M+E and 15.4% (6.0, 31.3) for E.”
> “Most common treatment-emergent adverse events (TEAEs) were diarrhea (78.0%), decreased appetite (58.5%), and dysgeusia (58.5%) for M+E, and asthenic conditions (42.5%), nausea (25.0%), and anemia (22.5%) for E. Grade ≥3 TEAEs were observed in 53.7% of pts in M+E (most common diarrhea, neutropenia and sepsis) and 42.5% in E. There were no treatment-related deaths.”

Source: [Schweizer et al. (2025)](https://ascopubs.org/doi/10.1200/JCO.2025.43.5_suppl.LBA138)

<a id="topic-2.1.2.14-2"></a>

### Mevrometostat plus enzalutamide: dose escalation after abiraterone or enzalutamide

> “As of November 2, 2023, 47 pts had received ≥1 dose of study treatment. Median (interquartile range) duration of follow up was 9.7 (2.0-22.8) months (mo).”
> “Median (95% CI) rPFS was 17.0 (6.3, not estimable [NE]) mo in the total population; 17.1 (6.2, NE) mo for pts who received prior A (without E) (n=12), and 11.7 (4.2, NE) mo for pts who received prior E (± A) (n=35).”
> “Adverse events (AEs) led to treatment discontinuation in 9 (19.1%) pts. The most common treatment-emergent AEs (TEAEs) considered related to M were diarrhea (42.6%), dysgeusia (42.6%), and anemia (36.2%). Grade ≥3 TEAEs considered related to M were reported in 17.0% of pts.”

Source: [Schweizer et al. (2024)](https://ascopubs.org/doi/10.1200/JCO.2024.42.16_suppl.5061)

<a id="topic-2.1.2.14-3"></a>

### Mevrometostat 875 mg with food plus enzalutamide: safety and selection of the phase 3 dose

> “As of Nov 15, 2024, 29 pts received M at 875mg with food + E. Median (interquartile range [IQR]) duration of treatment was 5.5 (4.1–7.4) months.”
> “The most common TEAEs of any grade related to M were diarrhea (41.4%), thrombocytopenia (41.4%), and dysgeusia (37.9%). Serious TEAEs related to M were reported in 3 (10.3%) pts (anemia, ECG QT prolonged, and hemorrhagic enterocolitis), all were grade 3. There were no grade 4 TEAEs. TEAEs led to withdrawal from M in 4 (13.8%) pts.”
> “M 875 mg with food + E was selected as the recommended dose for pivotal phase 3 studies.”

Source: [Matsubara et al. (2025)](https://ascopubs.org/doi/10.1200/JCO.2025.43.16_suppl.5046)

<a id="topic-2.1.2.14-4"></a>

### Mevrometostat 875 mg with food plus enzalutamide: efficacy after abiraterone, enzalutamide naive

> “As of September 1, 2025, 29 pts had received M 875 mg BID with food + E (2A, n=15; 2C, n=14).”
> “In 2A, 9 (60.0%) pts had received abiraterone and 9 (60%) pts had received E; in 2C, 14 (100%) pts received prior abiraterone and were E naive.”
> “median (90% CI) rPFS was 14.3 (2.0, not estimable [NE]) months in 2A and NE (6.2, NE) months in 2C. Confirmed PSA50 (95% CI) was observed in 6 (40.0%) (16.3, 67.7) pts in 2A and 6 (42.9%) (17.7, 71.1) pts in 2C.”
> “For 2A+2C combined, most common treatment-emergent AEs (TEAEs) were diarrhea (48.3%), thrombocytopenia (48.3%), and decreased appetite (44.8%). Grade ≥3 TEAEs were observed in 41.3% of pts (most common: thrombocytopenia, anemia, asthenic conditions, and hypokalemia). Grade ≥3 TEAEs considered related to M were reported in 31.0% pts.”

Source: [Matsubara et al. (2026)](https://ascopubs.org/doi/10.1200/JCO.2026.44.7_suppl.195)

<a id="topic-2.1.2.14-5"></a>

### Mevrometostat plus enzalutamide: MEVPRO-1 and MEVPRO-2 phase 3 designs

> “MEVPRO-1 ( NCT06551324 ) is an open-label, phase III trial which will evaluate mevrometostat plus enzalutamide versus physician’s choice of either enzalutamide or docetaxel in patients with mCRPC who have progressed following ≥12 weeks of treatment with abiraterone.”
> “Randomization will be stratified by previous docetaxel in the metastatic castration-sensitive prostate cancer (mCSPC) setting, physician’s choice of comparator (prespecified prior to randomization and will remain consistent throughout the study), and presence of hepatic metastases.”
> “MEVPRO-2 ( NCT06629779 ) is a double-blind, placebo-controlled, phase III trial that will evaluate mevrometostat plus enzalutamide versus enzalutamide alone in adult patients with mCRPC who are treatment-naïve”
> “The primary efficacy endpoint for both MEVPRO-1 and MEVPRO-2 is rPFS per RECIST 1.1 (soft tissue) and PCWG3 (bone) assessed by BICR. OS (alpha protected) is a key secondary endpoint in both studies.”
> “There will be no interim analysis for the primary endpoint (rPFS).”

Source: [Shore et al. (2026a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13203012/)

<a id="topic-2.1.2.14-6"></a>

### Mevrometostat plus enzalutamide: MEVPRO-1 enrollment and estimated primary completion

> “Pfizer MEVPRO-1 (C2321014) is a randomized, open-label, multi-center clinical trial evaluating whether combining the study medicine (PF-06821497) with enzalutamide is safe and effective compared to physician's choice of either second-line androgen receptor (AR) directed therapy with enzalutamide or docetaxel (chemotherapy) for treating metastatic castration-resistant prostate cancer (mCRPC) after progression on prior abiraterone acetate treatment.”
> “Active, not recruiting”
> “2027-02-28”

Source: [ClinicalTrials.gov NCT06551324](https://clinicaltrials.gov/study/NCT06551324)

<a id="topic-2.1.2.14-7"></a>

### Mevrometostat plus enzalutamide: MEVPRO-3 in metastatic castration-sensitive disease

> “This study will explore whether a combination of the investigational drug mevrometostat (PF-06821497) and enzalutamide will work better than taking enzalutamide alone in participants with mCSPC who are ARPI naïve and have not yet received chemotherapy in the mCSPC setting.”

Source: [ClinicalTrials.gov NCT07028853](https://clinicaltrials.gov/study/NCT07028853)

<a id="topic-2.1.2.14-8"></a>

### Tazemetostat plus enzalutamide: CELLO-1 randomized phase 2 after abiraterone

> “For phase 2 randomized component (i.e, enzalutamide- containing treatment arms) of the study, previously progressed on abiraterone.”
> “The study was terminated early as Sponsor decided to discontinue the development of tazemetostat in metastatic castration resistant prostate cancer and the primary endpoint was not met for this study. There were no safety concerns.”

Source: [ClinicalTrials.gov NCT04179864](https://clinicaltrials.gov/study/NCT04179864)

| Outcome | Tazemetostat 1200 mg twice daily plus enzalutamide | Enzalutamide |
| --- | --- | --- |
| Participants analyzed | “41” | “40” |
| Median rPFS, months (95% CI) | “22.1” (“16.6” to “27.6”) | “11.1” (“5.7” to “16.5”) |
| Confirmed PSA50 response, % (95% CI) | “19.5” (“8.82” to “34.87”) | “15.0” (“5.71” to “29.84”) |

Source: [ClinicalTrials.gov NCT04179864 results](https://clinicaltrials.gov/study/NCT04179864?tab=results)

<a id="topic-2.1.2.14-9"></a>

### Tazemetostat: market withdrawal for hematologic second primary malignancies

> “The U.S. Food and Drug Administration (FDA) is alerting patients and health care providers about the voluntary withdrawal of Tazverik (tazemetostat) tablets from the market due to an increased rate of hematologic second primary malignancies (SPMs)”
> “In this study, as of March 6, 2026, 18 out of 318 (5.7%) patients treated with Tazverik developed hematologic SPMs, compared to no reported events among patients in the control arm.”
> “Most participants who developed the new blood cancers were receiving Tazverik for 1-3 years. The SPMs started as early as 7.5 months after beginning treatment and occurred in some patients after stopping treatment.”

Source: [FDA Tazverik safety alert (2026)](https://www.fda.gov/drugs/drug-alerts-and-statements/fda-alerts-health-care-providers-and-patients-about-increased-risk-new-blood-cancers-tazverik)

> “Dedicated carcinogenicity studies were not conducted with tazemetostat, but T-LBL, MDS, AML, and B-ALL have been reported clinically and T-LBL occurred in juvenile and adult rats after ~9 or more weeks of tazemetostat administration during 13-week toxicity studies.”

Source: [Tazverik prescribing information (2024)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/211723s005lbl.pdf)

<a id="topic-2.1.2.14-10"></a>

### Class concern for hematologic malignancy with chronic PRC2 inhibition in prostate cancer

> “Mevrometostat, valemetostat, and tulmimetostat ( 18 – 20 ) have now been evaluated in several hundred patients. To date, no comparable secondary-malignancy signal has been publicly reported for these agents. This experience is reassuring but not yet definitive.”
> “In the phase 1/2 mevrometostat experience, median follow-up was approximately 9.6 months as of the September 2, 2024 data cut ( 21 ) substantially shorter than the interval over which therapy-related MDS/AML typically emerge.”
> “All of these factors are possible mediators of risk, though no published data currently link any specific pharmacologic property to differential second-malignancy risk.”

Source: [Alumkal and Ellis (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13552191/)

<a id="topic-2.1.2.14-11"></a>

### CPI-1205 plus enzalutamide or abiraterone: ProSTAR phase 1b/2

> “This was an open-label Phase 1b/2 study involving oral administration of CPI-1205 in combination with either enzalutamide or abiraterone/prednisone in male patients with metastatic Castration-Resistant Prostate Cancer.”

Source: [ClinicalTrials.gov NCT03480646](https://clinicaltrials.gov/study/NCT03480646)

| Outcome | CPI-1205 800 mg three times daily plus enzalutamide | Enzalutamide |
| --- | --- | --- |
| Best objective response rate, % (95% CI) | “7.89” (“1.66” to “21.38”) | “5.71” (“0.70” to “19.16”) |
| Composite response rate, % (95% CI) | “31.4” (“16.9” to “49.3”) | “17.1” (“6.6” to “33.6”) |

Source: [ClinicalTrials.gov NCT03480646 results](https://clinicaltrials.gov/study/NCT03480646?tab=results)

<a id="topic-2.1.2.14-12"></a>

### Company benchmark comparison: landmark rPFS and safety versus mevrometostat after abiraterone

| Regimen | Median follow-up | Month 3 rPFS | Month 4 rPFS | Month 5 rPFS | Grade 3 or higher TRAEs | Dose reductions / discontinuations |
| --- | --- | --- | --- | --- | --- | --- |
| Mevrometostat 875 mg twice daily fed plus enzalutamide (n=14) | “9.2” months | “92%” | “92%” | “84%” | “36%” | “7% / 7%” |
| Mevrometostat 1250 mg twice daily fasted plus enzalutamide (n=41) | “11.7” months | “92%” | “86%” | “80%” | “49%” | “37% / 2%” |
| Enzalutamide monotherapy (n=40) | “9.0” months | “78%” | “70%” | “60%” | “23%” | “8% / 5%” |
| Rinzimetostat 400 mg once daily plus darolutamide (n=18) | “4.9” months | “93%” | “84%” | “84%” | “6%” | “None / 6%” |

Source: [ORIC Pharmaceuticals presentation (2026)](https://www.sec.gov/Archives/edgar/data/1796280/000119312526134618/d133016dex991.htm)

> “Preliminary rinzimetostat rPFS landmark analysis, albeit early, compares favorably to competitor benchmarks with a far cleaner safety profile, despite more heavily pretreated patients”
> “Note: Competitor rPFS percentages estimated from published data.”
> “Cross-trial comparison in previously treated mCRPC patients shown.”

Source: [ORIC Pharmaceuticals presentation (2026)](https://www.sec.gov/Archives/edgar/data/1796280/000119312526134618/d133016dex991.htm)

<a id="topic-2.1.2.14-13"></a>

### Company benchmark comparison: serious adverse events and dose modifications versus mevrometostat

| Measure | Mevrometostat 875 mg twice daily fed plus enzalutamide (n=14) | Mevrometostat 1250 mg twice daily fasted plus enzalutamide (n=41) | Rinzimetostat 400 mg once daily plus darolutamide (n=18) |
| --- | --- | --- | --- |
| Grade 3 or higher TRAEs | “36%” | “49%” | “6%” |
| Serious TRAEs | “21%” | “24%” | “None” |
| Dose reductions | “7%” | “37%” | “None” |
| Treatment discontinuations | “7%” | “2%” | “6%” |

Source: [ORIC Pharmaceuticals presentation (2026)](https://www.sec.gov/Archives/edgar/data/1796280/000119312526134618/d133016dex991.htm)

<a id="topic-2.1.2.14-14"></a>

### Company comparison of rPFS across post-ARPI therapies

| Treatment | Status | Month 5 rPFS | Median rPFS, months |
| --- | --- | --- | --- |
| Enzalutamide | “Approved” | “60%” | “6.2” |
| Cabazitaxel | “Approved” | “65%” | “8.0” |
| Docetaxel | “Approved” | “75%” | “8.3” |
| Lutetium Lu 177 vipivotide tetraxetan | “Approved” | “75%” | “9.3” |
| Mevrometostat plus enzalutamide | “Phase 3” | “80% to 84%” | “~12 to 14” |
| Rinzimetostat plus darolutamide | “Starting” “Phase 3” | “84% to 85%” | “Not mature” |

Source: [ORIC Pharmaceuticals presentation (2026)](https://www.sec.gov/Archives/edgar/data/1796280/000119312526134618/d133016dex991.htm)

> “PRC2 inhibitors in combination with an AR inhibitor have demonstrated much longer rPFS (key regulatory primary endpoint) than what has been reported with other approved and emerging therapies”

Source: [ORIC Pharmaceuticals presentation (2026)](https://www.sec.gov/Archives/edgar/data/1796280/000119312526134618/d133016dex991.htm)

<a id="topic-2.1.2.14-15"></a>

### Company statements comparing dose optimization results with mevrometostat

> “The durability observed to date is consistent with the competitor PRC2 inhibitor currently in Phase 3 in mCRPC and appears meaningfully improved relative to other approved standard of care therapies.”
> “Notably, rinzimetostat demonstrated this impressive durability with a markedly cleaner safety profile than competitor regimens.”

Source: [ORIC Pharmaceuticals RP3D selection release (2026)](https://oricpharma.com/news/oric-pharmaceuticals-reports-selection-of-rinzimetostat-rp3d-in-combination-with-darolutamide-for-himalayas-1-phase-3-global-study-with-dose-optimization-data-supporting-its-potential-best-in-di/)

<a id="topic-2.1.2.14-16"></a>

### Company comparison of PRC2 inhibitor development status

| Product | Development status |
| --- | --- |
| CPI-1205 | “Discontinued” |
| Tazemetostat | “Discontinued” |
| Mevrometostat | “Phase 3 trials ongoing” |
| Rinzimetostat | “First Phase 3 initiation expected 1H 2026” |

Source: [ORIC Pharmaceuticals presentation (2026)](https://www.sec.gov/Archives/edgar/data/1796280/000119312526134618/d133016dex991.htm)

> “Rinzimetostat is a potential best-in-class PRC2 inhibitor that addresses the limitations of earlier generation PRC2 inhibitors”

Source: [ORIC Pharmaceuticals presentation (2026)](https://www.sec.gov/Archives/edgar/data/1796280/000119312526134618/d133016dex991.htm)

<a id="topic-2.1.2.14-17"></a>

### Company preclinical claims for EED targeting: EZH1 coverage and acquired resistance

> “Differential potency of PRC2 inhibitors on EZH1- vs. EZH2-containing complexes impacts activity in resistance contexts, providing potential advantages for EED targeting. Rinzimetostat retained antitumor activity in prostate cancer cells with overexpressed EZH1 in vitro, while potency was diminished for mevrometostat or tazemetostat.”

Source: [ORIC Pharmaceuticals AACR preclinical data release (2026)](https://oricpharma.com/news/oric-pharmaceuticals-presents-preclinical-data-to-support-the-potential-of-rinzimetostat-across-prostate-cancer-and-in-emerging-resistance-settings-at-the-2026-american-association-for-cancer-re/)

> “Prostate cancer cells that rapidly developed resistance to mevrometostat acquired a mutation in EZH2 against which rinzimetostat potency was maintained; no emergence of rinzimetostat-resistant cells was observed.”

Source: [ORIC Pharmaceuticals ESMO preclinical and translational data release (2026)](https://oricpharma.com/news/oric-pharmaceuticals-presents-preclinical-and-translational-data-to-support-the-potential-of-rinzimetostat-to-enhance-sensitivity-to-androgen-receptor-inhibition-in-prostate-cancer-at-esmo-congr/)

<a id="topic-2.1.2.14-18"></a>

### Company preclinical claims for hematologic tumorigenesis in rat toxicology versus tazemetostat

> “No hematologic tumorigenesis was observed in the rinzimetostat rat toxicology study, in contrast to rat tumorigenesis demonstrated with EZH2 inhibitor tazemetostat; these results are consistent with mouse genetic studies of PRC2 components and suggest the tumorigenesis risk may be elevated with selective EZH2 targeting.”

Source: [ORIC Pharmaceuticals ESMO preclinical and translational data release (2026)](https://oricpharma.com/news/oric-pharmaceuticals-presents-preclinical-and-translational-data-to-support-the-potential-of-rinzimetostat-to-enhance-sensitivity-to-androgen-receptor-inhibition-in-prostate-cancer-at-esmo-congr/)

> “EZH2 genetic deletion in mice induced hematologic malignancies, consistent with tazemetostat results in 13-week rat GLP tox study demonstrating tumorigenesis. EED genetic deletion in mice did not induce hematologic malignancy, consistent with rinzimetostat 13-week rat GLP tox study demonstrating no tumorigenesis.”

Source: [Friedman et al. (2026)](https://oricpharma.com/wp-content/uploads/2026/10/ESMO-2026_Rinzimetostat-Preclinical-Translational-Poster.pdf)

## Related pages
- [Rinzimetostat (ORIC-944): Metastatic castration-resistant prostate cancer previously treated with abiraterone, in combination with darolutamide](https://www.evicenter.com/drugs/rinzimetostat--metastatic-castration-resistant-prostate-cancer-previously-treated-with-abiraterone-in-combination-with-darolutamide) · [Markdown](https://www.evicenter.com/drugs/rinzimetostat--metastatic-castration-resistant-prostate-cancer-previously-treated-with-abiraterone-in-combination-with-darolutamide.md)
- [Rinzimetostat (ORIC-944) in Metastatic castration-resistant prostate cancer previously treated with abiraterone, in combination with darolutamide: Terms and abbreviations](https://www.evicenter.com/drugs/rinzimetostat--metastatic-castration-resistant-prostate-cancer-previously-treated-with-abiraterone-in-combination-with-darolutamide/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/rinzimetostat--metastatic-castration-resistant-prostate-cancer-previously-treated-with-abiraterone-in-combination-with-darolutamide/terms-and-abbreviations.md)
- [Rinzimetostat (ORIC-944): Metastatic castration-resistant prostate cancer previously treated with abiraterone, in combination with darolutamide](https://www.evicenter.com/drugs/rinzimetostat--metastatic-castration-resistant-prostate-cancer-previously-treated-with-abiraterone-in-combination-with-darolutamide/executive-summary) · [Markdown](https://www.evicenter.com/drugs/rinzimetostat--metastatic-castration-resistant-prostate-cancer-previously-treated-with-abiraterone-in-combination-with-darolutamide/executive-summary.md)
- [Rinzimetostat (ORIC-944) in Metastatic castration-resistant prostate cancer previously treated with abiraterone, in combination with darolutamide: Product information and disease description](https://www.evicenter.com/drugs/rinzimetostat--metastatic-castration-resistant-prostate-cancer-previously-treated-with-abiraterone-in-combination-with-darolutamide/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/rinzimetostat--metastatic-castration-resistant-prostate-cancer-previously-treated-with-abiraterone-in-combination-with-darolutamide/product-information-and-disease-description.md)
- [Rinzimetostat (ORIC-944) in Metastatic castration-resistant prostate cancer previously treated with abiraterone, in combination with darolutamide: Clinical evidence](https://www.evicenter.com/drugs/rinzimetostat--metastatic-castration-resistant-prostate-cancer-previously-treated-with-abiraterone-in-combination-with-darolutamide/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/rinzimetostat--metastatic-castration-resistant-prostate-cancer-previously-treated-with-abiraterone-in-combination-with-darolutamide/clinical-evidence.md)
- [Rinzimetostat (ORIC-944) in Metastatic castration-resistant prostate cancer previously treated with abiraterone, in combination with darolutamide: Economic information and modeling report](https://www.evicenter.com/drugs/rinzimetostat--metastatic-castration-resistant-prostate-cancer-previously-treated-with-abiraterone-in-combination-with-darolutamide/economics) · [Markdown](https://www.evicenter.com/drugs/rinzimetostat--metastatic-castration-resistant-prostate-cancer-previously-treated-with-abiraterone-in-combination-with-darolutamide/economics.md)
- [Rinzimetostat (ORIC-944) in Metastatic castration-resistant prostate cancer previously treated with abiraterone, in combination with darolutamide: References](https://www.evicenter.com/drugs/rinzimetostat--metastatic-castration-resistant-prostate-cancer-previously-treated-with-abiraterone-in-combination-with-darolutamide/references) · [Markdown](https://www.evicenter.com/drugs/rinzimetostat--metastatic-castration-resistant-prostate-cancer-previously-treated-with-abiraterone-in-combination-with-darolutamide/references.md)
